Recently, mTORC1 activation has been reported as a resistance mechanism in BRAF-mutant melanoma, and combining BRAF/MEKi with the mTORC1 inhibitor rapamycin was shown to effectively target resistant melanoma cells (69). The gene discussed is BRAF; the disease is melanoma.